Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients.

Coplan PM, Cepeda MS, Petronis KR, DeVeaugh-Geiss A, Barsdorf AI, Kern DM, Fanelli R.

Postgrad Med. 2020 Jan;132(1):44-51. doi: 10.1080/00325481.2019.1685793. Epub 2019 Nov 13.

PMID:
31721609
2.

Using natural language processing of clinical text to enhance identification of opioid-related overdoses in electronic health records data.

Hazlehurst B, Green CA, Perrin NA, Brandes J, Carrell DS, Baer A, DeVeaugh-Geiss A, Coplan PM.

Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1143-1151. doi: 10.1002/pds.4810. Epub 2019 Jun 19.

3.

Development of an algorithm to identify inpatient opioid-related overdoses and oversedation using electronic data.

Green CA, Hazlehurst B, Brandes J, Sapp DS, Janoff SL, Coplan PM, DeVeaugh-Geiss A.

Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1138-1142. doi: 10.1002/pds.4797. Epub 2019 May 16.

4.

Identifying and classifying opioid-related overdoses: A validation study.

Green CA, Perrin NA, Hazlehurst B, Janoff SL, DeVeaugh-Geiss A, Carrell DS, Grijalva CG, Liang C, Enger CL, Coplan PM.

Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1127-1137. doi: 10.1002/pds.4772. Epub 2019 Apr 24.

5.

Conditional power for assessing population interventions.

Walker AM, Coplan PM, Beachler DC.

J Comp Eff Res. 2018 Oct;7(10):1027-1035. doi: 10.2217/cer-2018-0053. Epub 2018 Aug 22.

6.

Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.

Cheng HG, Coplan PM.

Postgrad Med. 2018 Aug;130(6):568-574. doi: 10.1080/00325481.2018.1495541. Epub 2018 Jul 16.

PMID:
29978755
7.

Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.

Bucher Bartelson B, Le Lait MC, Green JL, Cepeda MS, Coplan PM, Maziere JY, Wedin GP, Dart RC.

Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1061-1070. doi: 10.1002/pds.4257. Epub 2017 Jul 31.

PMID:
28758289
8.

Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records.

Green CA, Perrin NA, Janoff SL, Campbell CI, Chilcoat HD, Coplan PM.

Pharmacoepidemiol Drug Saf. 2017 May;26(5):509-517. doi: 10.1002/pds.4157. Epub 2017 Jan 10.

PMID:
28074520
9.

Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.

Sessler NE, Walker E, Chickballapur H, Kacholakalayil J, Coplan PM.

Postgrad Med. 2017 Jan;129(1):62-68. doi: 10.1080/00325481.2016.1271698.

PMID:
27977317
10.

Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.

Coplan PM, Sessler NE, Harikrishnan V, Singh R, Perkel C.

Postgrad Med. 2017 Jan;129(1):55-61. doi: 10.1080/00325481.2017.1269596. Epub 2016 Dec 21.

PMID:
27922764
11.

Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis.

Yarborough BJ, Stumbo SP, Janoff SL, Yarborough MT, McCarty D, Chilcoat HD, Coplan PM, Green CA.

Drug Alcohol Depend. 2016 Oct 1;167:49-56. doi: 10.1016/j.drugalcdep.2016.07.024. Epub 2016 Aug 1.

PMID:
27520885
12.

ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.

Cepeda MS, Coplan PM, Kopper NW, Maziere JY, Wedin GP, Wallace LE.

Pain Med. 2017 Jan 1;18(1):78-85. doi: 10.1093/pm/pnw129.

13.

Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).

Chilcoat HD, Coplan PM, Harikrishnan V, Alexander L.

Drug Alcohol Depend. 2016 Aug 1;165:221-8. doi: 10.1016/j.drugalcdep.2016.06.009. Epub 2016 Jun 16.

14.

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.

Janoff SL, Perrin NA, Coplan PM, Chilcoat HD, Campbell CI, Green CA.

BMC Pharmacol Toxicol. 2016 May 14;17(1):21. doi: 10.1186/s40360-016-0064-y.

15.

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC.

Clin Pharmacol Ther. 2016 Sep;100(3):275-86. doi: 10.1002/cpt.390. Epub 2016 Jun 22. Erratum in: Clin Pharmacol Ther. 2017 Apr;101(4):541.

16.

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM.

Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1238-46. doi: 10.1002/pds.3658. Epub 2014 Jun 11.

17.

Impact of vaccination on the epidemiology of varicella: 1995-2009.

Baxter R, Tran TN, Ray P, Lewis E, Fireman B, Black S, Shinefield HR, Coplan PM, Saddier P.

Pediatrics. 2014 Jul;134(1):24-30. doi: 10.1542/peds.2013-4251. Epub 2014 Jun 9.

PMID:
24913796
18.

Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.

McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF.

J Med Internet Res. 2014 May 2;16(5):e119. doi: 10.2196/jmir.3397.

19.

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.

Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1274-82. doi: 10.1002/pds.3522. Epub 2013 Sep 30.

20.

Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.

Severtson SG, Bartelson BB, Davis JM, Muñoz A, Schneider MF, Chilcoat H, Coplan PM, Surratt H, Dart RC.

J Pain. 2013 Oct;14(10):1122-30. doi: 10.1016/j.jpain.2013.04.011. Epub 2013 Jun 29.

PMID:
23816949
21.

Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study.

Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, Lewis E, Fireman B, Saddier P.

Pediatrics. 2013 May;131(5):e1389-96. doi: 10.1542/peds.2012-3303. Epub 2013 Apr 1.

PMID:
23545380
22.

Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.

Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, Coplan PM.

J Pain. 2013 Apr;14(4):351-8. doi: 10.1016/j.jpain.2012.08.008. Epub 2012 Nov 3.

PMID:
23127293
23.

Application of the BRAT framework to case studies: observations and insights.

Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F.

Clin Pharmacol Ther. 2011 Feb;89(2):217-24. doi: 10.1038/clpt.2010.280. Epub 2010 Dec 22.

PMID:
21178990
24.

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.

Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F.

Clin Pharmacol Ther. 2011 Feb;89(2):312-5. doi: 10.1038/clpt.2010.291. Epub 2010 Dec 15. No abstract available.

PMID:
21160469
25.

Mathematical models and health economic aspects of microbicides.

Wilson DP, Coplan PM.

Curr Opin HIV AIDS. 2008 Sep;3(5):587-92. doi: 10.1097/COH.0b013e328305b959.

PMID:
19373026
26.

The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics.

Wilson DP, Coplan PM, Wainberg MA, Blower SM.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9835-40. doi: 10.1073/pnas.0711813105. Epub 2008 Jul 7. Erratum in: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6879.

27.

The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults.

Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN.

Clin J Pain. 2007 Jul-Aug;23(6):490-6.

PMID:
17575488
28.

Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma.

Coplan JD, Mathew SJ, Mao X, Smith EL, Hof PR, Coplan PM, Rosenblum LA, Gorman JM, Shungu DC.

Psychiatry Res. 2006 Jun 30;147(1):27-39. Epub 2006 Jun 22.

PMID:
16797939
29.

Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.

Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, Schechter M, Mbewe B, Vardas E, Pitisuttithum P, Burke D, Freed D, Mogg R, Coplan PM, Condra JH, Long RS, Anderson K, Casimiro DR, Shiver JW, Straus WL.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):135-9.

PMID:
16760794
30.

Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand.

Coplan JD, Altemus M, Mathew SJ, Smith EL, Sharf B, Coplan PM, Kral JG, Gorman JM, Owens MJ, Nemeroff CB, Rosenblum LA.

CNS Spectr. 2005 Jul;10(7):530-6.

PMID:
16155510
31.

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.

Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, Mbewe B, Vardas E, Schechter M, Kallas EG, Freed DC, Fu TM, Mast CT, Puthavathana P, Kublin J, Brown Collins K, Chisi J, Pendame R, Thaler SJ, Gray G, Mcintyre J, Straus WL, Condra JH, Mehrotra DV, Guess HA, Emini EA, Shiver JW.

J Infect Dis. 2005 May 1;191(9):1427-34. Epub 2005 Mar 30.

PMID:
15809900
32.

Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory.

Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN.

J Pain. 2004 Aug;5(6):344-56.

PMID:
15336639
33.

Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.

Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ; AIDS Clinical Trials Group 320 Study Team.

Clin Infect Dis. 2004 Aug 1;39(3):426-33. Epub 2004 Jul 19.

PMID:
15307012
34.

Public health. Regulatory challenges in microbicide development.

Coplan PM, Mitchnick M, Rosenberg ZF.

Science. 2004 Jun 25;304(5679):1911-2. No abstract available.

PMID:
15218130
35.
36.

Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors.

Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, Lewis R, Xu Y, DiNubile MJ.

AIDS Res Hum Retroviruses. 2003 Jun;19(6):449-55.

PMID:
12882653
37.

Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men.

Fife KH, Coplan PM, Jansen KU, DiCello AC, Brown DR, Rojas C, Su L.

Sex Transm Dis. 2003 Mar;30(3):246-8.

PMID:
12616145
38.
39.

Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina.

Clements DA, Zaref JI, Bland CL, Walter EB, Coplan PM.

Arch Pediatr Adolesc Med. 2001 Apr;155(4):455-61.

PMID:
11296072
40.

The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data.

Markey P, Krause V, Boslego JW, Coplan PM, Dargan JM, Kaplan KM.

Epidemiol Infect. 2001 Feb;126(1):31-6.

41.

The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings.

Pellissier JM, Coplan PM, Jackson LA, May JE.

Am J Manag Care. 2000 Sep;6(9):1038-44.

42.

Hepatitis B vaccination and the risk of multiple sclerosis.

Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM.

N Engl J Med. 2001 Feb 1;344(5):327-32.

44.

Postlicensure study of varicella vaccine effectiveness in a day-care setting.

Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB.

Pediatr Infect Dis J. 1999 Dec;18(12):1047-50.

PMID:
10608622
45.

Human immunodeficiency virus infection in Mexico City. Rectal bleeding and anal warts as risk factors among men reporting sex with men.

Coplan PM, Gortmaker S, Hernandez-Avila M, Spiegelman D, Uribe-Zuñiga P, Mueller NE.

Am J Epidemiol. 1996 Nov 1;144(9):817-27.

PMID:
8890660
46.

Supplemental Content

Loading ...
Support Center